Eosinophil chemotaxis inhibitor

Details Eosinophil chemotaxis inhibitor Eosinophil chemotaxis inhibitor

1998-05-01

1999-07-13

Spivack, Phyllis G.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

A61K 3150

Patent

active

059227125

ABSTRACT:
A method for inhibiting eosinophil infiltration by administrating to a subject in need thereof an effective amount of a compound of the formula: ##STR1## wherein R.sup.2 and R.sup.3 independently represent a hydrogen atom or a C.sub.1-4 group, and R.sup.4a and R.sup.5a independently represent a hydrogen atom or a C.sub.1-4 alkyl group, or a pharmaceutically acceptable salt thereof.

REFERENCES:
patent: 5011835 (1991-04-01), Peet et al.
patent: 5039689 (1991-08-01), Daluge
Berkow et al., "The Merck Manual" Merck Research Laboratories, USA 16th edition, chapter 98, pp. 1230-1231 (1992).
Labrakis-Lazanas, Katerina et al., "PAF of Biological Fluids in Disease: Blood Levels in Allergic Rhinitis" vol. 73, pp. 379-382; Haematologica (1998).
Chemical Abstract AN 93-153853, Korth, to EP 540766, (1993).
Chemical Abstracts, AN 1990:629449 Misawa et al., (1990).
Chemical Abstracts, AN 1990:214771 Fukuda et al., (1990).

Affiliated with

Also associated with

Rating

Eosinophil chemotaxis inhibitor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Eosinophil chemotaxis inhibitor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Eosinophil chemotaxis inhibitor will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2275910